| James Robert Blake Miller, PT, DPT, ATC | |
|
705 Tranquil Trl, Grand Junction, CO 81507-9532 | |
| (406) 363-8388 | |
| Not Available |
| Full Name | James Robert Blake Miller |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 5 Years |
| Location | 705 Tranquil Trl, Grand Junction, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043871338 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 16436 (Colorado) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Slope Accident Care, Llc | 5294133658 | 2 |
News Archive
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Researchers have identified 23 new longevity genes by screening the genome of Caenorhabditis elegans, a small worm that is used as a model organism in genetics studies. The findings are reported in the inaugural issue of PLoS Genetics.
Scleroderma clinicians and researchers in the United States and China have launched an international network to fight this debilitating disease that affects more than one million people worldwide.
Researchers investigate potentially amyloidogenic peptide fragments that could be associated with the neurological symptoms of COVID-19 and long-COVID.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.
› Verified 9 days ago
| Provider Name | Panorama Orthopedics And Spine Center Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1295787950 PECOS PAC ID: 8426961087 Enrollment ID: O20031110000424 |
News Archive
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Researchers have identified 23 new longevity genes by screening the genome of Caenorhabditis elegans, a small worm that is used as a model organism in genetics studies. The findings are reported in the inaugural issue of PLoS Genetics.
Scleroderma clinicians and researchers in the United States and China have launched an international network to fight this debilitating disease that affects more than one million people worldwide.
Researchers investigate potentially amyloidogenic peptide fragments that could be associated with the neurological symptoms of COVID-19 and long-COVID.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.
› Verified 9 days ago
| Provider Name | Western Slope Accident Care, Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1679248470 PECOS PAC ID: 5294133658 Enrollment ID: O20211015000144 |
News Archive
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Researchers have identified 23 new longevity genes by screening the genome of Caenorhabditis elegans, a small worm that is used as a model organism in genetics studies. The findings are reported in the inaugural issue of PLoS Genetics.
Scleroderma clinicians and researchers in the United States and China have launched an international network to fight this debilitating disease that affects more than one million people worldwide.
Researchers investigate potentially amyloidogenic peptide fragments that could be associated with the neurological symptoms of COVID-19 and long-COVID.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Robert Blake Miller, PT, DPT, ATC 705 Tranquil Trl, Grand Junction, CO 81507-9532 Ph: (406) 363-8388 | James Robert Blake Miller, PT, DPT, ATC 705 Tranquil Trl, Grand Junction, CO 81507-9532 Ph: (406) 363-8388 |
News Archive
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Researchers have identified 23 new longevity genes by screening the genome of Caenorhabditis elegans, a small worm that is used as a model organism in genetics studies. The findings are reported in the inaugural issue of PLoS Genetics.
Scleroderma clinicians and researchers in the United States and China have launched an international network to fight this debilitating disease that affects more than one million people worldwide.
Researchers investigate potentially amyloidogenic peptide fragments that could be associated with the neurological symptoms of COVID-19 and long-COVID.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.
› Verified 9 days ago
Murray Thiessen, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2635 N 7th St, Grand Junction, CO 81501 Phone: 970-298-2041 | |
Traci Terhaar, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3049 Stoneybrook Ln, Grand Junction, CO 81504 Phone: 970-401-0950 | |
Ms. Susan Rebecca Harris, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2497 Power Rd Unit 10, Grand Junction, CO 81507 Phone: 970-263-4079 Fax: 970-241-2595 | |
Mr. Luke David Geer, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 321 Rood Ave, Grand Junction, CO 81501 Phone: 970-242-0111 Fax: 970-263-4334 | |
Randall Akers, PTA Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2472 Patterson Rd Unit 9, Grand Junction, CO 81505 Phone: 970-245-0511 Fax: 970-245-1025 | |
Kathryn Faye Kossa, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2121 North Ave, Grand Junction, CO 81501 Phone: 970-242-0731 |